Skip to content

Study · Randomized controlled trial · n = 38 · 2017

5 results

Effect of continuous exenatide infusion on cardiac function and peri-operative glucose control in patients undergoing cardiac surgery: A single-blind, randomized controlled trial.

Lipš M, Mráz M, Kloučková J, Kopecký P, Dobiáš M, Křížová J, Lindner J, Diamant M, Haluzík M

Diabetes, obesity & metabolism31 Jul 2017Cited by 29 (Europe PMC)

PMID28581209 (opens in a new tab)DOI10.1111/dom.13029 (opens in a new tab)PepBankPUB-28581209
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In cardiac surgery patients, exenatide did not significantly alter postoperative echocardiographic variables versus placebo.

    In plain wordsIn cardiac surgery patients, exenatide did not significantly change heart ultrasound results compared with placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changePostoperative echocardiographic variables
    Study

    n = 38

    Comparator
    Placebo with standard peri-operative insulin
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated · intravenous · 72 hoursAs given in this study (human).

    Source sentences

    Summary
    While no significant difference in postoperative echocardiographic variables was found between the groups,
    1 context sentence
    Summary · context
    A total of 38 patients with decreased left ventricular systolic function (ejection fraction ≤50%) scheduled for elective coronary artery bypass grafting (CABG) were randomized to receive either exenatide or placebo in a continuous 72-hour intravenous (i.v.) infusion on top of standard peri-operative insulin therapy.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In cardiac surgery patients, exenatide lowered average peri-operative glycaemia versus placebo.

    In plain wordsIn cardiac surgery patients, exenatide lowered average blood sugar compared with placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseAverage glycaemia
    Study

    n = 38

    Comparator
    Placebo with standard peri-operative insulin
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · intravenous · 72 hoursAs given in this study (human).

    Measurements

    Average peri-operative glycaemia
    6.4 mmol/L
    Exenatide group
    Average peri-operative glycaemia
    7.3 mmol/L
    Placebo group

    Source sentences

    Summary
    participants receiving exenatide showed improved peri-operative glucose control as compared with the placebo group (average glycaemia 6.4 ± 0.5 vs 7.3 ± 0.8 mmol/L; P < .001;
    1 context sentence
    Summary · context
    A total of 38 patients with decreased left ventricular systolic function (ejection fraction ≤50%) scheduled for elective coronary artery bypass grafting (CABG) were randomized to receive either exenatide or placebo in a continuous 72-hour intravenous (i.v.) infusion on top of standard peri-operative insulin therapy.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In cardiac surgery patients, exenatide increased time in the target glucose range versus placebo.

    In plain wordsIn cardiac surgery patients, exenatide increased time within the blood sugar target compared with placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseTime in target glucose range
    Study

    n = 38

    Comparator
    Placebo with standard peri-operative insulin
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · intravenous · 72 hoursAs given in this study (human).

    Measurements

    Percentage of time in target range 4.5-6.5 mmol/L
    54.8%
    Exenatide group
    Percentage of time in target range 4.5-6.5 mmol/L
    38.6%
    Placebo group

    Source sentences

    Summary
    percentage of time in target range of 4.5-6.5 mmol/L 54.8% ± 14.5% vs 38.6% ± 14.4%; P = .001;
    1 context sentence
    Summary · context
    A total of 38 patients with decreased left ventricular systolic function (ejection fraction ≤50%) scheduled for elective coronary artery bypass grafting (CABG) were randomized to receive either exenatide or placebo in a continuous 72-hour intravenous (i.v.) infusion on top of standard peri-operative insulin therapy.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In cardiac surgery patients, exenatide decreased time above the target glucose range versus placebo.

    In plain wordsIn cardiac surgery patients, exenatide decreased time above the blood sugar target compared with placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseTime above target glucose range
    Study

    n = 38

    Comparator
    Placebo with standard peri-operative insulin
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · intravenous · 72 hoursAs given in this study (human).

    Measurements

    Percentage of time above target range
    39.7%
    Exenatide group
    Percentage of time above target range
    52.8%
    Placebo group

    Source sentences

    Summary
    percentage of time above target range 39.7% ± 13.9% vs 52.8% ± 15.2%; P = .009)
    1 context sentence
    Summary · context
    A total of 38 patients with decreased left ventricular systolic function (ejection fraction ≤50%) scheduled for elective coronary artery bypass grafting (CABG) were randomized to receive either exenatide or placebo in a continuous 72-hour intravenous (i.v.) infusion on top of standard peri-operative insulin therapy.
  5. 05HumanRandomized controlled trialSafety outcome

    In cardiac surgery patients, exenatide did not significantly increase hypoglycaemia versus placebo.

    In plain wordsIn cardiac surgery patients, exenatide did not significantly increase low blood sugar compared with placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeHypoglycaemia
    Study

    n = 38

    Comparator
    Placebo with standard peri-operative insulin
    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    Dose not stated · intravenous · 72 hoursAs given in this study (human).

    Measurements

    Hypoglycaemia episodes (glycaemia <3.3 mmol/L)
    0.1 episodes per participant
    Exenatide group
    Hypoglycaemia episodes (glycaemia <3.3 mmol/L)
    0.21 episodes per participant
    Placebo group

    Source sentences

    Summary
    without an increased risk of hypoglycaemia (glycaemia <3.3 mmol/L: 0.10 ± 0.32 vs 0.21 ± 0.42 episodes per participant; P = .586).
    1 context sentence
    Summary · context
    A total of 38 patients with decreased left ventricular systolic function (ejection fraction ≤50%) scheduled for elective coronary artery bypass grafting (CABG) were randomized to receive either exenatide or placebo in a continuous 72-hour intravenous (i.v.) infusion on top of standard peri-operative insulin therapy.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3NCT01373216

Glucagon-like Peptide 1 Agonist Exenatide for Improved Glucose Control and Cardiac Function in Patients With Aortocoronary Bypass

Charles University, Czech Republicn = 38Jun 2011 to Dec 2014

Coronary Artery Disease · Decreased Left Ventricular Function

Trial pageClinicalTrials.govUpdated 2 Feb 2016

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.